Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisParis, December 24, 2025.

Taking lipoic acid failed to ease progressive MS symptoms in a clinical trial, but the antioxidant showed signs of slowing ...

Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...

Early studies of biotin as a treatment for multiple sclerosis (MS) were promising, showing that it was well tolerated and brought sustained reversal of MS-related disability. More recent studies, ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.

By Dennis Thompson HealthDay ReporterWEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic ...

The SPRINT-MS trial evaluated the novel drug ibudilast over 96 weeks in patients with primary and secondary progressive multiple sclerosis. The SPRINT-MS trial was a phase II clinical trial of ...

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®. A recent interview with Kathy M. Zackowski, PhD, OTR, senior director, patient ...

Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...

The role of imaging in diagnosing progressive multiple sclerosis (MS) and in assessing prognosis is the subject of a new review. MRI is central in the diagnostic workup of patients suspected of having ...